(Total Views: 437)
Posted On: 03/23/2020 8:16:10 PM
Post# of 154251
Smlf,
Thanks. Yes, I consider myself a technical investor. I abandoned "discretionary" trading many years ago.
What I have been doing in my last decades is to trade based on my own technical indicators. I use primarily correlation and volume analysis. As well, of course, I had hard diversification rules that served me well until now.
All this to tell you that abandoning my "trusty" rules was not easy …
I originally invested in CYDY in basis of HIV only (I believed that the lack of adverse events was a winner, and still feel the same), and, in researching the why, and the possibility of oncology applications as well, I reached the conclusion that this was an opportunity that could not be passed … and started to buy more and more …
Some years down the road I think the end is approaching rapidly and that I made the right decision. And yes, you are right, the SP has held extremely well under the circumstances that we have seen for the market at large. And yes, the amount of possible indications of Leronlimab can be an excellent proxy for diversification.
Thanks. Yes, I consider myself a technical investor. I abandoned "discretionary" trading many years ago.
What I have been doing in my last decades is to trade based on my own technical indicators. I use primarily correlation and volume analysis. As well, of course, I had hard diversification rules that served me well until now.
All this to tell you that abandoning my "trusty" rules was not easy …
I originally invested in CYDY in basis of HIV only (I believed that the lack of adverse events was a winner, and still feel the same), and, in researching the why, and the possibility of oncology applications as well, I reached the conclusion that this was an opportunity that could not be passed … and started to buy more and more …
Some years down the road I think the end is approaching rapidly and that I made the right decision. And yes, you are right, the SP has held extremely well under the circumstances that we have seen for the market at large. And yes, the amount of possible indications of Leronlimab can be an excellent proxy for diversification.
(2)
(0)
